Skip to main navigation Skip to search Skip to main content

COVID-19 Vaccine Anaphylaxis: Current Evidence and Future Approaches

Research output: Contribution to journalShort surveypeer-review

16 Citations (Scopus)

Abstract

Vaccine anaphylaxis is rare; however, severe allergic reactions after administration of a coronavirus disease 2019 (COVID-19) vaccines have been reported. Excipients in the vaccine may play a role in severe allergic reactions post-vaccination. Various mechanisms, including IgE-mediated pathways, direct mass cell stimulation via the Mas-related G protein-coupled receptor-X2, and complement pathway activation, have been proposed to cause the anaphylaxis. Skin testing, using the basophil activation test, has been used to clarify the mechanism of the anaphylaxis and provide safety information for the next injection. Here, we review the current evidence and suggested approaches for patients who experienced an immediate severe allergic reaction to the first dose of a COVID-19 vaccine.

Original languageEnglish
Article number801322
JournalFrontiers in Allergy
Volume2
DOIs
Publication statusPublished - 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • COVID-19 vaccine safety
  • IgE mediated
  • allergy
  • anaphylaxis
  • hypersensitivity

Fingerprint

Dive into the research topics of 'COVID-19 Vaccine Anaphylaxis: Current Evidence and Future Approaches'. Together they form a unique fingerprint.

Cite this